down arrow

Sutro Biopharma, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8693671021
USD
9.38
8.65 (1185.28%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Assertio Holdings, Inc.
IGM Biosciences, Inc.
Akebia Therapeutics, Inc.
scPharmaceuticals, Inc.
Y-mAbs Therapeutics, Inc.
Enanta Pharmaceuticals, Inc.
Sutro Biopharma, Inc.
Praxis Precision Medicines, Inc.
Ocular Therapeutix, Inc.
Lifecore Biomedical, Inc.
AEON Biopharma, Inc.
Why is Sutro Biopharma, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate -190.98% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -19.58
2
The company has declared Negative results for the last 3 consecutive quarters
  • NET SALES(9M) At USD 95.95 MM has Grown at -37.05%
  • OPERATING CASH FLOW(Y) Lowest at USD -248.86 MM
  • NET PROFIT(9M) At USD -120.44 MM has Grown at -35.51%
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -67.05%, its profits have fallen by -72.3%
4
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -67.05% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sutro Biopharma, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Sutro Biopharma, Inc.
239.86%
-0.64
121.76%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
21.05%
EBIT Growth (5y)
-190.98%
EBIT to Interest (avg)
-19.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.97
Sales to Capital Employed (avg)
0.45
Tax Ratio
0.97%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.77
EV to EBIT
-0.09
EV to EBITDA
-0.09
EV to Capital Employed
-0.27
EV to Sales
0.31
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

24What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -4.32% (YoY

NET SALES(Q)

Highest at USD 63.74 MM

OPERATING PROFIT(Q)

Highest at USD 16.98 MM

OPERATING PROFIT MARGIN(Q)

Highest at 26.63 %

PRE-TAX PROFIT(Q)

Highest at USD 6.91 MM

NET PROFIT(Q)

Highest at USD 6.92 MM

EPS(Q)

Highest at USD -0.14

-17What is not working for the Company
NET SALES(9M)

At USD 95.95 MM has Grown at -37.05%

OPERATING CASH FLOW(Y)

Lowest at USD -248.86 MM

NET PROFIT(9M)

At USD -120.44 MM has Grown at -35.51%

INTEREST(HY)

At USD 18.99 MM has Grown at 31.24%

ROCE(HY)

Lowest at -347.64%

DEBT-EQUITY RATIO (HY)

Highest at -45.3 %

Here's what is working for Sutro Biopharma, Inc.
Net Sales
At USD 63.74 MM has Grown at 147.98%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely positive

Net Sales (USD MM)

Pre-Tax Profit
At USD 6.91 MM has Grown at 113.07%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 6.92 MM has Grown at 113.11%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales
Highest at USD 63.74 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD 16.98 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at 26.63 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at USD 6.91 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD 6.92 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -0.14
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost
Fallen by -4.32% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sutro Biopharma, Inc.
Operating Cash Flow
Lowest at USD -248.86 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest
At USD 18.99 MM has Grown at 31.24%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio
Highest at -45.3 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."